New physiopathological and therapeutic approaches to diverticular disease: An update

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 7, 2014, Pages 1005-1017

  Tursi, Antonio ^a  

^a ASL BAT   (Italy)

Author keywords

5 aminosalycilic acid; Acute diverticulitis; High fiber diet; Nonabsorbale antibiotics; Probiotics; Symptomatic uncomplicated diverticular disease

Indexed keywords

AMINOSALICYLIC ACID; BALSALAZIDE; CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; NARCOTIC ANALGESIC AGENT; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SPASMOLYTIC AGENT; VSL3;

ACUTE DISEASE; ANTIBIOTIC THERAPY; COLON DIVERTICULOSIS; DIET THERAPY; HIGH FIBER DIET; HUMAN; LACTOBACILLUS CASEI; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RECURRENT DISEASE; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLON; DIETARY FIBER; DIVERTICULOSIS, COLONIC; HUMANS; MESALAMINE; PROBIOTICS; RECURRENCE;

EID: 84899421994     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.903922     Document Type: Review

References (92)

1. Tursi A, Papagrigoriadis S. Review article: the current and evolving treatment of colonic diverticular disease. Aliment Pharmacol Ther 2009;30:532-46
2. Fong SS, Tan EY, Foo A, et al. The changing trend of diverticular disease in a developing nation. Colorectal Dis 2011;13:312-16
3. Alatise OI, Arigbabu AO, Agbakwuru EA, et al. Spectrum of colonoscopy findings in Ile-Ife Nigeria. Niger Postgrad Med J 2012;19:219-24
4. Boles RS Jr, Jordan SM. The clinical significance of diverticulosis. Gastroenterology 1958;35:579-82
5. Aydin HN, Remzi FH. Diverticulitis: when and how to operate? Dig Liver Dis 2004;36:435-45
6. Floch M, Bina I. The natural history of diverticulitis-fact and theory. J Clin Gastroenterol 2004;38(Suppl 1):S2-7
7. Aldoori WH, Giovannucci EL, Rimm EB, et al. A prospective study of diet and the risk of symptomatic diverticular disease in men. Am J Clin Nutr 1994;60:757-64
8. Sheth AA, Longo W, Floch MH. Diverticular disease and diverticulitis. Am J Gastroenterol 2008;103:1550-6
9. Klarenbeek BR, de Korte N, van der Peet DL, Cuesta MA. Review of current classifications for diverticular disease and a translation into clinical practice. Int J Colorectal Dis 2012;27:207-14
10. Köhler L, Sauerland S, Neugebauer E. Diagnosis and treatment of diverticular disease: result of a Consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc 1999;13:430-6
11. Tursi A, Brandimarte G, Elisei W, et al. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009;24:49-55
12. Cuomo R, Barbara G, Andreozzi P, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013;43:1147-55
13. Tursi A, Elisei W, Picchio M, et al. Moderate-to-severe and prolonged left lower abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol 2014. [Epub ahead of print]
14. Ambrosetti P. Acute diverticulitis of the left colon: value of the initial CT and timing of elective colectomy. J Gastrointest Surg 2008;12:1318-20
15. Flor N, Rigamonti P, Pisani Ceretti A, et al. Diverticular disease severity score based on CT colonography. Eur Radiol 2013;23:2723-9
16. Ghorai S, Ulbright TM, Rex DK. Endoscopic findings of diverticular inflammation in colonoscopy patients without clinical acute diverticulitis: prevalence and endoscopic spectrum. Am J Gastroenterol 2003;98:802-6
17. Tursi A, Elisei W, Giorgetti GM, et al. Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. Aliment Pharmacol Ther 2011;33:358-65
18. Tursi A. Diverticular disease: a therapeutic overview. World J Gastrointest Pharmacol Ther 2010;1:27-35
19. Narayan R, Floch MH. Microscopic colitis as part of the natural history of diverticular disease. Am J Gastroenterol 2002;97(Suppl 1):12
20. Tursi A, Brandimarte G, Elisei W, et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008;42:699-703
21. Cianci R, Iacopini F, Petruzziello L, et al. Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol 2009;44:108-15
22. Tursi A, Elisei W, Brandimarte G, et al. Predictive value of serologic markers of degree of histologic damage in acute uncomplicated colonic diverticulitis. J Clin Gastroenterol 2010;44:702-6
23. Simpson J, Sundler F, Humes DJ, et al. Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterol Motil 2009;21:847-58
24. Tursi A, Elisei W, Brandimarte G, et al. Musosal tumour necrosis factor-alpha in diverticular disease of the colon is overexpressed with disease severity. Colorectal Dis 2012;14:e258-63
25. Humes DJ, Simpson J, Smith J, et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 2012;24:318-e163
26. Smith J, Humes D, Garsed K, et al. Mechanistic randomised control trial of mesalazine in symptomatic diverticular disease. Gut 2012;61:A51-2
27. Tursi A, Elisei W, Brandimarte G, et al. Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study. Neurogastroenterol Motil 2012;24:836-e396
28. Batra A, Siegmund B. The role of visceral fat. Dig Dis 2012;30:70-4
29. Tursi A, Elisei E, Giorgetti GM, et al. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. J Gastrointest Liver Dis 2013;22:12-17
30. Bargellini T, Martellucci J, Tonelli P, Valeri A. Long-term results of treatment of acute diverticulitis: still lessons to be learned? Updates Surg 2013;65:125-30
31. Scarpa M, Pagano D, Ruffolo C, et al. Health-related quality of life after colonic resection for diverticular disease: long-term results. J Gastrointest Surg 2009;13:105-12
32. Floch MH. A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol 2006;40(Suppl 3):S121-5
33. Tursi A. Colonic microflora imbalance and diverticular disease. Dig Liver Dis 2010;42:458
34. World Gastroenterology Organisation (WGO) Practice Guidelines 2007. Diverticular disease. Available from: http://www.worldgastroenterologyorg/ assets/downloads/en/pdf/guidelines/07-diverticular-diseasepdf2007 [Accessed 15 April 2008]
35. Unlü C, Daniels L, Vrouenraets BC, Boermeester MA. A systematic review of high-fibre dietary therapy in diverticular disease. Int J Colorectal Dis 2012;27:419-27
36. Lamanna A, Orsi A. In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984;3:365-7
37. Papi C, Ciaco A, Koch M, Capurso L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995;9:33-9
38. Latella G, Pimpo MT, Sottili S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18:55-62
39. Bianchi M, Festa V, Moretti A, et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther 2011;33:902-10
40. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol 2000;95:3343-5
41. Tursi A, Joseph RE, Streck P. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci 2011;56:3112-21
42. Kruis W, Meier E, Schumacher M, et al.; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon-a placebo-controlled study. Aliment Pharmacol Ther 2013;37:680-90
43. Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease-a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013;38:741-51
44. Bermudez-Brito M, Plaza-D́iaz J, Munoz-Quezada S, et al. Probiotic mechanisms of action. Ann Nutr Metab 2012;61:160-74
45. Humes DJ, Spiller RC. Review article: the pathogenesis and management of acute colonic diverticulitis. Aliment Pharmacol Ther 2014;39:359-70
46. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006;40:312-16
47. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008;55:916-20
48. Annibale B, Maconi G, Lahner E, et al. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterol Dietol 2011;57:13-22
49. Lahner E, Esposito G, Zullo A, et al. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 2012;18:5918-24
50. Tursi A. Advances in the management of colonic diverticulitis. CMAJ 2012;184:1470-6
51. Rafferty J, Shellito P, Hyman NH, et al. Practice parameters for sigmoid diverticulitis. Dis Colon Rectum 2006;49:939-44
52. Schechter S, Mulvey J, Eisenstat TE. Management of uncomplicated acute diverticulitis: results of a survey. Dis Colon Rectum 1999;42:470-5
53. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999;94:3110-21
54. Abbas MA, Cannom RR, Chiu VY, et al. Triage of patients with acute diverticulitis: are some inpatients candidates for outpatient treatment? Colorectal Dis 2013;15:451-7
55. Schug-Pass C, Geers P, Hügel O, et al. Prospective randomized trial comparing short-term antibiotic therapy versus standard therapy for acute uncomplicated sigmoid diverticulitis. Int J Colorectal Dis 2010;25:751-9
56. Moya P, Arroyo A, Pérez-Legaz J, et al. Applicability, safety and efficiency of outpatient treatment in uncomplicated diverticulitis. Tech Coloproctol 2012;16:301-7
57. Biondo S, Golda T, Kreisler E, et al. Outpatients versus hospitalisation management for uncomplicated diverticulitis: a prospective, multicenter randomised clinical trila (DIVER Trial). Ann Surg 2014;259:38-44
58. de Korte N, Kuyvenhoven JP, van der Peet DL, et al. Mild colonic diverticulitis can be treated without antibiotics. A case-control study. Colorectal Dis 2012;14:325-30
59. Chabok A, Pahlman L, Hjern F, et al. AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. Br J Surg 2012;99:532-9
60. Unlü C, de Korte N, Daniels L, et al. Multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). BMC Surg 2010;10:23
61. Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo in acute uncomplicated diverticulitis. Available from: http://clinicaltrials.gov/ct2/show/NCT01847664 (NCT01847664)
62. Binda GA, Arezzo A, Serventi A, et al. Multicentre observational study on the natural history of left-sided acute diverticulitis. Br J Surg 2012;99:276-85
63. Ogawa K, Nishijima K, Futagami F, et al. Effectiveness of traditional japanese hernal (Kampo) medicine, daiobotampito, in combination with antibiotic therapy in the treatment of acute diverticulitis: a preliminary study. Evid Based Complement Alternat Med 2013;2013:305414
64. Scheid V, Bensky D, Ellis A, Barolet R chinese herbal medicine formulas & strategies. 2nd edition. Eastland Press, Seattle, Wash, USA; 2009
65. Shahedi K, Fuller G, Bolus R, et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol 2013;11:1609-13
66. Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and non-vegetarians. BMJ 2011;343:d4131
67. Peery AF, Barrett PR, Park D, et al. A high-fiber diet does not protect against asymptomatic diverticulosis. Gastroenterology 2012;142:266-72
68. Strate LL, Liu YL, Syngal S, et al. Nut, corn, and popcorn consumption and the incidence of diverticular disease. JAMA 2008;300:907-14
69. Lanas A, Ponce J, Bignamini A, Mearin F. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Dig Liver Dis 2013;45:104-9
70. Singeap AM, Trifan A, Cojocariu C, et al. Clinical benefit and protective role against acute diverticulitis of non-absorbable antibiotics with cyclic administration in diverticular colonic disease. UEG Journal 2013;1(Suppl 1):A245
71. Zullo A, Hassan C, Maconi G, et al. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. J Gastrointest Liver Dis 2010;19:295-302
72. Maconi G, Barbara G, Bosetti C, et al. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Dis Colon Rectum 2011;54:1-12
73. Stocchi L. Current indications and role of surgery in the management of sigmoid diverticulitis. World J Gastroenterol 2010;16:804-17
74. Egger B, Peter MK, Candinas D. Persistent symptoms after elective sigmoid resection for diverticulitis. Dis Colon Rectum 2008;51:1044-8
75. Stollman N, Magowan S, Shanahan F, Quigley EM, DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 2013;47:621-9
76. Parente F, Bargiggia S, Prada A, et al.; "Gismi Study Group". Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. Int J Colorectal Dis 2013;28:1423-31
77. Prevention of Recurrence of Diverticulitis (PREVENT 1) (NCT00545740). Available from: http://www.clinicaltrials. gov/ct2/show/NCT00545740
78. Prevention of Recurrence of Diverticulitis (PREVENT 2) (NCT00545103). Available from: http://www.clinicaltrials. gov/ct2/show/NCT00545103
79. Kruis W, Eisenbach T, Löhr H, et al. Double-blind, randomized, placebo-controlled, multicenter trial of mesalamine for the prevention of recurrence of diverticulitis. Gastroenterology 2013;144(5 Suppl 1): S-139
80. Gaman A, Teodorescu R, Georhescu EF, Abagiu MT. Prophylactic effects of mesalamine in diverticular disease [abstract 13]. Falk Symposium 178; 2011
81. Giaccari S, Tronci S, Falconieri M, Ferrieri A. Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur Rev Med Pharmacol Sci 1993;15(1):29-34
82. Tursi A, Brandimarte G, Giorgetti GM, et al. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007;22:1103-8
83. Dughera L, Serra AM, Battaglia E, et al. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. Minerva Gastroenterol Dietol 2004;50:149-53
84. Krokowicz L, Stojcev Z, Kaczmarek BF, et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis-a prospective randomized study. Int J Colorectal Dis 2014;29:387-93
85. Banasiewicz T, Krokowicz L, Stojcev Z, et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis 2013;15:204-9
86. Cordel S, Dupas B, Douillard JY, Meflah K. Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. Int J Cancer 1998;78:735-9
87. Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Investig 2003;33:244-8
88. Principi M, Giorgio F, Losurdo G, et al. Fibrogenesis and fibrosis in inflammatory bowel diseases: good and bad side of same coin? World J Gastrointest Pathophysiol 2013;4:100-7
89. Ierardi E, Giorgio F, Piscitelli D, et al. Altered molecular pattern of mucosal healing in Crohn's disease fibrotic stenosis. World J Gastrointest Pathophysiol 2013;4:53-8
90. Tursi A, Elisei W, Giorgetti GM, et al. Expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-alpha in resected acute colonic diverticulitis. Colorectal Dis 2014;16:098-13
91. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):15-38
92. Tursi A, Brandimarte G, Di Mario F, et al. Development and validation of an endoscopic classification of diverticular disease of the colon: the DICA classification. Dig Dis 2014. [Epub ahead of print]